Poumon non à petites cellules

  • Accueil
  • Poumon non à petites cellules
  • 2023-11332

TITRE (EN) This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention
PROTOCOLE ID 2023-11332
CLINICAL TRIAL.gov ID NCT05805319
TYPE(S) DE CANCER Poumon non à petites cellules
PHASE Autres
TYPE D'ÉTUDE Support
INSTITUTION CHUM
1051 rue Sanguinet
(514) 890-8000
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Bertrand Routy
COORDONATEUR(RICE) Wiam Belkaid
wiam.belkaid.chum@ssss.gouv.qc.ca
514-890-8000
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Signed, informed consent
  • Age 18 years or older
  • Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI
  • Ability to eat solid foods
CRITÈRES D'EXCLUSION (EN)
  • Severe dietary allergies (e.g. shellfish, nuts, seafood)
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.